REG - CVS Group plc - Response to CMA Summary Final Decision Report

CVSAnnouncement

Yesterday 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260324:nRSX8560Xa&default-theme=true

RNS Number : 8560X  CVS Group plc  24 March 2026

For Immediate
Release
                       24 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Response to CMA Summary Final Decision Report

 

CVS notes this morning's publication by the Competition and Markets Authority
("CMA") of the summary of its Final Decision Report in the veterinary services
market investigation. The CMA is expected to publish its full Final Decision
Report later today.

 

CVS welcomes the certainty that this morning's announcement brings after more
than two and half years of CMA scrutiny.

 

The CMA's final decision does not introduce any new remedies over and above
those announced in its provisional decision.  We are pleased to see that the
CMA has considered our and the veterinary profession's feedback in amending
the proposed fee cap on prescriptions with the cap now increased to £21
inclusive of VAT for the first drug prescribed, with the ability to charge an
additional £12.50 for each additional drug prescribed at the same time.
 Whilst we continue to believe that some of these remedies are not fully
justified, we are comfortable with them and believe they are workable.  We
already comply with many remedies and are well advanced in complying with
others, with price lists published on our practice websites in late 2025 and
117 CVS UK companion animal practices already jointly branded.

 

As such, the Board expects the Group to continue to trade in line with market
expectations.

 

Whilst the remedies are now certain and will not change, we look forward to
discussing the practical implementation of all remedies with the CMA prior to
the publication of its Final Order later in 2026 which will bring these
remedies into legal effect.

 

Contacts

CVS Group plc
 
via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Camarco (Financial
PR)

Ginny Pulbrook
 
   cvsg@camarco.co.uk (mailto:cvsg@camarco.co.uk)

Tilly
Butcher
            +44 (0)20 3757 4980

Letaba Rimell
 

 

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk) )

CVS Group is a leading provider of veterinary services, operating in the UK
and Australia, listed on the Main Market of the London Stock Exchange.  CVS
is focused on providing high-quality clinical services to its clients and
their animals, with outstanding and dedicated clinical teams and support
colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and
3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RSPPPURUWUPQUMC



            Copyright 2019 Regulatory News Service, all rights reserved